A novel immunotherapeutic known as IMCgp100 induced clinical responses with manageable toxicity in patients with advanced melanoma, according to results from a phase I clinical trial presented at the 2014 AACR Annual Meeting.
Secondary endpoint results from a multicenter, randomized phase 3 trial showed talimogene laherparepvec conferred greater benefit than granulocyte-macrophage colony-stimulating factor for patients with unresected stage IIIB/IIIC or stage IV melanoma, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting in New York.
The investigational drug DEDN6526A, which is a new member of a class of drugs called antibody-drug conjugates, was safe, tolerable, and showed hints of activity against different forms of melanoma—cutaneous, mucosal, and ocular—according to results of a first-in-human phase I clinical trial presented here at the AACR Annual Meeting 2014, April 5-9.
